Drugs / AXER-204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03989440 | Jul 2019 → Jun 2022 | spinal cord injury | ReNetX Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXER-204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03989440 ↗ |
| Action | Inhibit | “Soluble Nogo-Receptor-Fc decoy (AXER-204) blocks inhibitors of axon growth and promotes recovery of motor function after SCI in animals.” PMID 37479373 ↗ Aug 2023 |
| Modality | Protein / enzyme biologic | “AXER-204 is a human fusion protein that acts as a soluble decoy/trap for the myelin-associated inhibitors of axonal growth known as Nogo-A, MAG, and OMgp.” NCT03989440 ↗ |
| Route | Intrathecal | “AXER-204 was delivered open label as single intrathecal doses of 3 mg, 30 mg, 90 mg, or 200 mg” PMID 37479373 ↗ Aug 2023 |